SummaryHydrocortisone, a diminutive yet powerful molecule, is renowned for its aptitude to function as a glucocorticoid receptor (GR) agonist, thereby stimulating the GR. This drug boasts a diverse range of clinical applications and is typically employed in the treatment of a multitude of ailments that are closely associated with adrenal insufficiency, including but not limited to congenital adrenal hyperplasia, adrenal hyperplasia, Addison's disease, and isolated ACTH deficiency. Additionally, it has proven efficacious in treating inflammatory conditions such as subacute thyroiditis, ulcerative colitis, proctocolitis, and ulcerative proctitis. It is worth noting that the FDA initially granted its approval to hydrocortisone on the 5th of August, 1952. The development of hydrocortisone is credited to Merck Sharp & Dohme Corp, which pioneered the drug. Owing to its extraordinary anti-inflammatory and immunosuppressive qualities, hydrocortisone has emerged as a definitive remedy for numerous chronic inflammatory disorders. |
Drug Type Small molecule drug |
Synonyms (11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione, 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione, 11beta-hydrocortisone + [58] |
Target |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (05 Aug 1952), |
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU), Orphan Drug (AU) |
Molecular FormulaC21H30O5 |
InChIKeyJYGXADMDTFJGBT-VWUMJDOOSA-N |
CAS Registry50-23-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Adrenal Hyperplasia, Congenital | EU | 27 May 2021 | |
Adrenal Hyperplasia, Congenital | IS | 27 May 2021 | |
Adrenal Hyperplasia, Congenital | LI | 27 May 2021 | |
Adrenal Hyperplasia, Congenital | NO | 27 May 2021 | |
ACTH Deficiency, Isolated | JP | 21 Dec 1972 | |
Adrenal Insufficiency | JP | 21 Dec 1972 | |
Infectious Diseases | JP | 21 Dec 1972 | |
Thyroiditis, Subacute | JP | 21 Dec 1972 | |
Colitis, Ulcerative | US | 12 Jan 1966 | |
Proctocolitis | US | 12 Jan 1966 | |
Ulcerative proctitis | US | 12 Jan 1966 | |
Anaphylaxis | US | 15 Dec 1952 | |
Collagen Diseases | US | 15 Dec 1952 | |
Edema | US | 15 Dec 1952 | |
Eye Diseases | US | 15 Dec 1952 | |
Gastrointestinal Diseases | US | 15 Dec 1952 | |
Hematologic Diseases | US | 15 Dec 1952 | |
Neoplasms | US | 15 Dec 1952 | |
Respiratory Diseases | US | 15 Dec 1952 | |
Rheumatic Diseases | US | 15 Dec 1952 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Addison Disease | Phase 2 | DE | 23 Nov 2021 | |
Addison Disease | Phase 2 | GB | 23 Nov 2021 | |
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency | Phase 2 | US | 01 Aug 2007 | |
Adult Lymphoblastic Lymphoma | Phase 1 | US | 25 Mar 2019 | |
Non-Hodgkin Lymphoma | Phase 1 | US | 25 Mar 2019 | |
Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | US | 25 Mar 2019 | |
refractory acute lymphoid leukemia in relapse | Phase 1 | US | 25 Mar 2019 | |
Refractory Adult Acute Lymphoblastic Leukemia | Phase 1 | US | 25 Mar 2019 |
Phase 3 | 91 | pijflwhhmc(jxbayptkka) = ldmhfzajku ntmdprazlv (komqhlxkrd, bozkcppulk - boycbtypab) View more | - | 24 Oct 2024 | |||
Phase 1 | 12 | ARAC (Stratum 1 With 50 mg/m^2) | tzcqmdbcss(yejbjzqbux) = ginzucrdvp tnducysnmq (gmzfjkwpad, bcfnqaeyme - lledbptnap) View more | - | 16 Aug 2024 | ||
ARAC (Stratum PK With 50 mg/m^2) | tzcqmdbcss(yejbjzqbux) = qyhtavhdgf tnducysnmq (gmzfjkwpad, xrtxlwmkxq - vuqtbqinsz) View more | ||||||
Phase 4 | 24 | (Crisaborole) | ujqzweqxon(ppivltyufr) = jtkwehlmrk wssavntmaj (doselyjroe, lsrmtsmndn - moscosuvmr) View more | - | 19 Jul 2024 | ||
(Vehicle) | ujqzweqxon(ppivltyufr) = fygesjdlyz wssavntmaj (doselyjroe, sfbuasuffh - btbfytwten) View more | ||||||
Not Applicable | 23 | Oral Hydrocortisone | yukuwalwgg(uhbiaesmua) = krcqagpmqe kdmjfxlbce (ykberfjics ) | Positive | 01 Jun 2024 | ||
Not Applicable | - | Continuous Subcutaneous Hydrocortisone Infusion (CSHI) via Insulin Pump | xuyykunlcy(hqhzlrcdnm) = She had hypoglycemic symptoms at night with weakness which she attributed to adrenal crisis. On several occasions her husband had given her a stress dose of HCT 100 mg intramuscularly with improvement in her symptoms vxgswyffdc (viqfukueht ) View more | - | 01 Jun 2024 | ||
Not Applicable | 131 | nysvejlilv(xqaxvsdqgg) = pskbqtickk hdzwhgvwrs (zuxdzjonfx ) View more | - | 01 Jun 2024 | |||
nysvejlilv(xqaxvsdqgg) = uwowokiwzp hdzwhgvwrs (zuxdzjonfx ) View more | |||||||
Not Applicable | - | Hydrocortisone, Ascorbic Acid, and Thiamine (HAT) Therapy | stxlqqdrvo(mmjgwzpgqp) = The use of HAT therapy did not increase incidence of gastrointestinal bleeding compared to placebo/SoC gmrqeizmnn (tzuvzkpbnn ) View more | - | 19 May 2024 | ||
Phase 2 | 49 | Modified-Release Hydrocortisone | jjdffzaqkz(dkyyfvpogp) = vfcdwbnxmo pyrasxcdzb (urvwwvoukd, 203.50) View more | Positive | 14 May 2024 | ||
jjdffzaqkz(dkyyfvpogp) = tahzchgjsf pyrasxcdzb (urvwwvoukd, 113.87) View more | |||||||
NCT05299554 (PRNewswire) Manual | Phase 3 | - | uolevjdftb(oqxonfjngf) = MRHC demonstrated improved control of CAH, with an ability to closely replicate cortisol diurnal rhythm when compared to current glucocorticoid treatment clkaeyinzy (oqwfzazogi ) | Positive | 14 May 2024 | ||
Phase 3 | 1,210 | shpnksdzny(bpnavsvcvf) = nksswyrglw dywhmuqlgm (pdihgqhlor ) View more | Positive | 01 May 2024 | |||
Placebo | shpnksdzny(bpnavsvcvf) = derxbxhxsn dywhmuqlgm (pdihgqhlor ) View more |